Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ensysce Biosciences Inc (ENSC)

Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,252
  • Shares Outstanding, K 7,329
  • Annual Sales, $ 2,230 K
  • Annual Income, $ -10,610 K
  • 60-Month Beta 0.77
  • Price/Sales 2.07
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ENSC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.06
  • Most Recent Earnings $-1.13 on 03/15/24
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.78
  • Number of Estimates 3
  • High Estimate -0.53
  • Low Estimate -1.05
  • Prior Year -2.08
  • Growth Rate Est. (year over year) +62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5300 +7.74%
on 04/19/24
0.8668 -34.13%
on 04/04/24
-0.2591 (-31.21%)
since 03/19/24
3-Month
0.5300 +7.74%
on 04/19/24
2.0600 -72.28%
on 01/24/24
-0.5690 (-49.91%)
since 01/19/24
52-Week
0.5300 +7.74%
on 04/19/24
7.2000 -92.07%
on 05/09/23
-4.0662 (-87.69%)
since 04/19/23

Most Recent Stories

More News
Stocks Set to Open Mixed as Investors Await FOMC Minutes, U.S. Payrolls Data

September S&P 500 futures (ESU23) are down -0.08%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.01% this morning at the start of a holiday-shortened week, with market participants looking...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
AAPL : 165.00 (-1.22%)
NVDA : 762.00 (-10.00%)
MCHP : 81.68 (-3.00%)
ON : 60.71 (-3.53%)
CCL : 14.12 (-0.42%)
NKE : 94.53 (-1.26%)
G.M.DX : 22.670 (+0.40%)
TSLA : 147.05 (-1.92%)
NIO : 3.80 (-5.00%)
LI : 26.38 (-9.60%)
Ensysce Biosciences (NASDAQ: ENSC) Successfully Completes Overdose-Protection Study

Ensysce Biosciences, Inc. (NASDAQ: ENSC) operates as a clinical-stage biotechnology company, which is focused on leveraging its proprietary technology to

ENSC : 0.5710 (-1.59%)
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences,...

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)
Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)
Ensysce Biosciences Secures $8 Million Convertible Note Financing

~ Additional Funding from Investor Cohort Validates Company's Mission ~

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting

- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)
Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

~ Nasal Opioid Abuse Being Explored for PF614 ~

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results

Corporate Update Call to be Held Tuesday, May 17, 2022 SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage...

ENSC : 0.5710 (-1.59%)
ENSCW : 0.0360 (-8.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp.,...

See More

Key Turning Points

3rd Resistance Point 0.6865
2nd Resistance Point 0.6470
1st Resistance Point 0.6090
Last Price 0.5710
1st Support Level 0.5315
2nd Support Level 0.4920
3rd Support Level 0.4540

See More

52-Week High 7.2000
Fibonacci 61.8% 4.6521
Fibonacci 50% 3.8650
Fibonacci 38.2% 3.0779
Last Price 0.5710
52-Week Low 0.5300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar